Complera® Registration In The Developing World

Approved

| 1. | Argentina | December 2015 |
|----|------------|----------------|
| 2. | Aruba | September 2013 |
| 3. | Azerbaijan | April 2015 |
| 4. | Bolivia | September 2013 |
| 5. | Chile | June 2013 |
| 6. | Colombia | January 2015 |
| 7. | Costa Rica | March 2013 |
| 8. | Curacao | May 2014 |
| | | |

| 9. | El Salvador | December 2015 |
|-----|-------------|----------------|
| 10. | Guyana | July 2016 |
| 11. | Haiti | May 2013 |
| 12. | Honduras | May 2014 |
| 13. | Jamaica | November 2013 |
| 14. | Mexico | May 2016 |
| 15. | Panama | April 2016 |
| 16. | Paraguay | September 2013 |

| 17. | Ukraine | July 2015 |
|-----|-----------|--------------|
| 18. | Uruguay | January 2014 |
| 19. | Venezuela | May 2016 |

Filed

| 1. | Dominican Republic | October 2015 |
|----|--------------------|----------------|
| 2. | Guatemala | September 2015 |
| 3. | Sint Maarten | January 2016 |

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Note

There can be no guarantee that marketing approval for Complera®/Eviplera® will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.



November 2017 www.gilead.com